5326122026-01-012026-03-315326122026-03-315326122025-03-315326122025-04-012026-03-315326122026-01-012026-03-31in-capmkt:OtherExpenses1Member5326122026-01-012026-03-31in-capmkt:OtherExpenses2Member5326122025-04-012026-03-31in-capmkt:OtherExpenses1Member5326122025-04-012026-03-31in-capmkt:OtherExpenses2Member5326122026-03-31OtherNoncurrentFinancialAssetsDomain15326122026-03-31OtherNoncurrentAssetsDomain15326122026-03-31OtherCurrentFinancialAssetsDomain15326122026-03-31OtherCurrentAssetsDomain15326122026-03-31OtherCurrentAssetsDomain25326122026-03-31OtherNoncurrentFinancialLiabilitiesDomain15326122026-03-31OtherNoncurrentFinancialLiabilitiesDomain25326122026-03-31OtherNoncurrentLiabilitiesDomain15326122026-03-31OtherCurrentFinancialLiabilitiesDomain15326122026-03-31OtherCurrentFinancialLiabilitiesDomain25326122026-03-31OtherCurrentLiabilitiesDomain15326122026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15326122025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15326122026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15326122025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15326122026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532612INDOCONOTLISTEDINE873D01024INDOCO REMEDIES LIMITEDMain BoardEquity2025-04-012026-03-312026-05-072026-04-27INRLakhsQuarterlyFourth quarterSingle segmentPHARMACEUTICAL2026-05-0711:05:002026-05-0712:30:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated4756100000-40000047557000001091800000325200000-6900000109410000045920000032490000017548000005043100000-28740000037400000-25000000029600000-42800000-132000000-2368000000000-236800000114400000-122400000-216400000-20400000-102000000-204000001846000002-2.57-2.5600-2.57-2.561. The audited Consolidated Results for the Quarter and Year ended 31st March, 2026, have been reviewed by the Audit committee and approved by the Board of Director of the Company at its meeting held on 07th May, 2026. The Statutory Auditors have expressed an Unmodified Audit opinion on these audited Consolidated Financial Results. <BR> <BR> 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. <BR> <BR> 3. The Board of Directors have proposed, subject to the approval of shareholders in the ensuing Annual General Meeting a Dividend of 10% i.e. 0.20 per equity share on face value of Rs. 2/-each to its equity shareholder's for the year 2025-2026. <BR> <BR> 4. In Nomination and Remuneration Committee meeting held on 03rd February 2026, the Company has allotted 55,700 number of equity shares to Indoco Employees Welfare Trust under Indoco Remedies Limited Employee Stock Option Plan-2022. <BR> <BR> 5.The company has only one primary reportable segment of activity, namely, Pharmaceuticals. <BR> <BR> 6. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: <BR> (Rs. in lakhs) <BR> --------------------------------------------------------------------------------------------------------------------------------- <BR> Net Sales Qtr ended Qtr ended Qtr ended Year ended Year ended <BR> & Income 31-03-2026 31-12-2025 31-03-2025 31-03-2026 31-03-2025 <BR> from Operations (Audited) (Unaudited) (Audited) (Audited) (Audited) <BR> ---------------------------------------------------------------------------------------------------------------------------------- <BR> <BR> India 24,714 29,544 26,186 1,12,412 1,09,039 <BR> Outside India 20,876 13,890 12,203 66,882 55,090 <BR> --------------------------------------------------------------------------------------------------------------------------------------- <BR> Total : 45,590 43,434 38,389 1,79,294 1,64,129 <BR> =================================================================== <BR> <BR> 7. The Consolidated Financials Results includes the results of the following Companies <BR> ------------------------------------------------------------------------------------------------------------------------- <BR> Name of the Company % of shareholding Consolidated as <BR> -------------------------------------------------------------------------------------------------------------------------- <BR> Xtend Industrial Designers & Engineers Pvt. Ltd. 100 Subsidiary <BR> Indoco Remedies Czech S R O 100 Subsidiary <BR> Indoco Remedies UK Ltd. 100 Subsidiary <BR> Warren Remedies Private Limited 100 Subsidiary <BR> FPP Holding Company, LLC 85 Subsidiary <BR> ----------------------------------------------------------------------------------------------------------------------------- <BR> 8. Figures for the quarter ended 31.3.2026 and 31.3.2025 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2025 (limited reviewed) and 31.12.2024 (limited reviewed). <BR> <BR> 9. (*) Exceptional items during the year includes : <BR> (a) Consideration received Rs. 346 lakhs for grant to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company, <BR> (b) Loss amounting to Rs. 213 lakhs on sale and leaseback of its Non current Assets, and, <BR> (c) Impact of past period employee benefit liability amounting to Rs. 427 lakhs due to implementation of the New Labour Codes. <BR> <BR> 10. Effective 21" November, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Group has assessed the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs. 427 lakhs primarily arising due to change in definition of "wages" for employees and contract labours. Considering the materiality and nonrecurring nature of this impact, the Group has presented such incremental impact under 'Exceptional Item" in the consolidated financial results for the year ended 31st March, 2026. The Group continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards.2025-04-012026-03-31AuditedConsolidated18453200000333000001848650000042560000001435500000-274100000425690000012225000001264500000736090000019522200000-1035700000-29400000-106510000030200000-108300000-781000000-9870000000000-987000000126200000-860800000-951500000-35500000-825300000-3550000018460000029208200000-10.7-10.6900-10.7-10.69Research & Development Expense177600000Other Expenses1577200000Research & Development Expense795400000Other Expenses656550000096983000002829000002152000002017600000617200000146000003270000013100000017830000098970000013999200000405210000004891700000259300000706000004650000012850000053966000002156000002269200000119335000002593270000018460000092082000009392800000-717000009321100000516020000045090000056111000003565000004360000074900000608610000051983000009026000002182600000308520000011905000009474000000582700000468800000105255000001661160000025932700000Other Financial Assets131000000Other Non-Current Assets989700000Other Financial Assets128500000Other Current Assets2035100000Assets Classified as held for Sale234100000Lease Liabilities423400000Other Financial Liabilities27500000Other Non-Current Liabilities74900000Lease Liabilities115600000Other Financial Liabilities1074900000Other Current Liabilities5827000001222500000141400000-13742000000-160600000-144100000-4600000-1085000000105010000003512000000126450000001730000016700000294100000477600000-8590000001370000068000000009250000060000000304910000019840000000006170000001922300000000000004664000001475300000000000000000000000137000000-20900000-101610000000013000000000014650000008868000001096000001910000012270000000-3500000-7680000001382000000138200000121100000259300000Items that will not be reclassified to profit and loss4140000041400000Items that will not be reclassified to profit and loss1840000018400000103000004600000Items that may be reclassified to profit or loss8570000085700000Items that may be reclassified to profit or loss126200000126200000240000013800000114400000126200000AuditedtrueM/s. Gokhale & Sathetrue2027-02-28